UVA research leads to new lifeline for leukemia patients

March 18, 2026
Gloved hand analyzing a sample under a microscope.

Acute myeloid leukemia remains a deadly cancer affecting thousands each year. A newly approved drug, ziftomenib, offers a targeted treatment option for some patients. (Illustration by John DiJulio, University Communications)

After repeated unsuccessful cancer treatments, even the strongest patients can lose hope. But former University of Virginia School of Medicine assistant professors Tomasz Cierpicki and Jolanta Grembecka are working to restore hope for people facing the deadliest form of blood cancer.

In November, the U.S. Food and Drug Administration approved ziftomenib for patients with recurrent or treatment-resistant acute myeloid leukemia with a NPM1 gene mutation.

Acute myeloid leukemia is a deadly blood cancer primarily seen in people over the age of 68. More than 22,000 Americans develop the condition each year, and more than 11,000 die, according to the American Cancer Society.

Portrait of Tomasz Cierpicki and Jolanta Grembecka.

Former UVA School of Medicine assistant professors Tomasz Cierpicki and Jolanta Grembecka, now at the University of Michigan, say their newly approved leukemia drug is offering hope to patients. “We feel even more motivated to continue our efforts,” Grembecka said. (Photo by Leisa Thompson, University of Michigan)

But those numbers could be on the decline thanks to Cierpicki and Grembecka.

“What Tomasz and Jolanta started in a UVA research lab two decades ago is now saving lives,” said UVA Licensing & Ventures Group Executive Director Richard W. Chylla. “This is precisely the type of outcome we hope for with all of the work that comes through our office here at LVG, and an example of the work we expect to be accomplished at the Paul and Diane Manning Institute of Biotechnology.”

Natives of Poland, Cierpicki and Grembecka – who are married and now professors at the University of Michigan – met while in graduate school at Wroclaw University of Technology in Poland. While there, they began thinking about research aimed at developing new drugs to help cancer patients.

“It was a dream, but at the time, we didn’t realize it could actually become a reality,” Grembecka said.

“Nobody could foresee the future,” Cierpicki said.

It was while working as assistant professors in Âé¶čÆÆœâ°æ Department of Molecular Physiology and Biological Physics in 2008 under mentor John Bushweller that the couple homed in on menin inhibitors, a class of targeted therapies used primarily to treat acute leukemias.

“We really value what John Bushweller did – he allowed us to have some independent work,” Cierpicki said. “And we were quite lucky that we got funding that could support what was needed to initiate and then continue the menin inhibitor project.”

There were many late nights.

Discovery and Innovation: Daily research. Life-changing results.
Discovery and Innovation: Daily research. Life-changing results.

“To some degree, it helped that we were married and worked together to support each other, but one of the issues is that when you work with your spouse, your work-related conversations continue even after you get home, so sometimes that is maybe too much,” Cierpicki said.

“We would sometimes start a conversation at midnight with an idea that couldn’t wait until the next day,” Grembecka said. “But on the positive side, we could closely collaborate with each other and use our complementary expertise while working on different aspects of the same project.”

Eventually, those conversations paid off. In 2009, the menin inhibitors that would eventually lead to the development of ziftomenib were patented through a collaboration between UVA Licensing & Ventures Group and the University of Michigan Innovation Partnership Office.

The drug blocks a key protein that drives leukemia, allowing cells to become healthy white blood cells instead of cancer cells.

“Ziftomenib is a long-awaited and desperately needed new option for patients for whom other treatments have failed – for patients left with no hope,” said Mark Esser, the head and chief scientific officer of the Manning  Institute. “It’s a wonderful achievement by Drs. Grembecka and Cierpicki.”

Grembecka said she and her husband have learned of patients who have had several unsuccessful treatments for their leukemia, only for the disease to go into remission after just one cycle of ziftomenib.

“The FDA approval of Ziftomenib is deeply rewarding, as the drug is now available to all patients who may need it,” Grembecka said. “It’s very inspiring as well. We feel even more motivated to continue our efforts.”

Cierpicki smiled when reflecting on his time at UVA.

“I believe academic drug discovery plays a very important role, particularly in rare diseases where industry interest may not be a primary priority,” he said. “Continuing these efforts is therefore essential.”

Media Contacts

Whitelaw Reid

Manager of Strategic Communications University of Virginia Licensing & Ventures Group

The Latest From Research & Discovery